Recent Updates
Recently added Catalysts
VNDA Positive Sentiment

Federal Court Allows Vanda Pharmaceuticals

Friday, January 19, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Vanda Pharmaceuticals has achieved a significant legal victory as the United States Court of Federal Claims allowed part of its lawsuit against the United States to proceed. The case pertains to Vanda's claims of an uncompensated taking of its trade secrets by the FDA. This ruling permits Vanda to continue seeking compensation while entering the discovery phase of the litigation. The implications of this case could greatly impact Vanda's operations and the broader pharmaceutical landscape.
Price reaction · baseline $3.69 (2024-01-18 close) · hit after-hours · 1 other VNDA headline(s) in the window, move may be shared
day 0 close · peak
-0.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Court's decision allows Vanda's claim to move forward.
  • Vanda is actively seeking compensation for its trade secrets.
  • The ruling could lead to significant findings during discovery.

CONCERNS & RISKS

  • The case involves complex legal proceedings.
  • Ongoing litigation introduces uncertainty for Vanda.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+121%
120-day peak, hindsight
Typical move
19.9%
average across 7 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
Imsidolimab
Phase 2 · Palmoplantar Pustulosis

Full Press Release Details

WASHINGTON, Jan. 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the United States Court of Federal Claims in Washington, D.C. denied in part the government's motion to dismiss Vanda's claim against the United States for the Food and Drug Administration's (FDA) uncompensated taking of Vanda's trade secrets and confidential information (Vanda Pharmaceuticals Inc. v. USA, case no. 1:23-cv-00629-AOB). Vanda is seeking compensation from the United States for the takings it contends occurred through the FDA's improper communication and disclosure of trade secrets and confidential information to certain generic drug manufacturers.
Vanda filed this lawsuit on May 1, 2023, and the United States moved to dismiss. On January 8, 2024, the Court held an oral argument on the government's motion. On January 18, 2024, the Court denied the government's motion in part, allowing Vanda's takings claim to move forward.
Vanda now intends to engage in discovery to support its claims.
About Vanda Pharmaceuticals Inc.
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.

Frequently Asked Questions

What recent legal action did Vanda Pharmaceuticals take?

Vanda Pharmaceuticals filed a lawsuit against the U.S. over alleged compensation for trade secrets.

What was the court's ruling regarding Vanda's claims?

The court partially denied the government's motion to dismiss Vanda's takings claim.

When did Vanda file its lawsuit?

Vanda filed the lawsuit on May 1, 2023.

What is Vanda seeking from the United States?

Vanda seeks compensation for the FDA's alleged improper disclosure of its trade secrets.

What steps will Vanda take following the court's decision?

Vanda plans to engage in discovery to support its claims.

ShareAdd on Google
Tags: VNDA Viatris Investor Conferences Healthcare Vanda Pharmaceuticals FDA trade secrets court ruling generic drug manufacturers
Last updated: Jan 19, 2024

Biotech snapshot

Cash runway
$170M liquidity · $10M/mo burn
~16 mo
Low dilution risk
Lead asset
ImsidolimabPhase 2
Palmoplantar Pustulosis →

Catalyst track record

+121%
best trade around VNDA's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for VNDA.

See every catalyst's timing & PoA →